SCHEMBL4548035

SCHEMBL4548035

CC(=O)Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.70
EPHX2 P34913 2/20 0.70
CYP3A4 P08684 1/20 0.65
APEX1 P27695 1/20 0.65
CA2 P00918 1/20 0.63
CA4 P22748 1/20 0.63
CA5A P35218 1/20 0.63
CA9 Q16790 1/20 0.63
IDO1 P14902 1/20 0.62
NPC1 O15118 3/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
RAB9A P51151 2/20 0.61
KDM4E B2RXH2 1/20 0.61
MAPT P10636 1/20 0.61
PKM P14618 1/20 0.61
LMNA P02545 1/20 0.61
ADORA3 P0DMS8 1/20 0.61
CHRM1 P11229 1/20 0.61
SLC6A2 P23975 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6815301 0.89 ALDH1A1 (0.65) EPHX1EPHX2IDO1MEN1KMT2A
SCHEMBL864429 0.84 SMN1; SMN2 (0.79) EPHX2CA2NPC1MEN1KMT2A
SCHEMBL31198183 0.84 HSD17B10 (0.59) EPHX2CYP3A4CA2CA4CA9
SCHEMBL5674663 0.84 HSD17B10 (0.59) EPHX2CYP3A4CA2CA4CA9
SCHEMBL3786387 0.84 CA1 (0.58) CA2CA9NPC1MEN1KMT2A
SCHEMBL405569 0.84 SMN1; SMN2 (0.59) EPHX1EPHX2NPC1KMT2ALMNA
SCHEMBL13602308 0.84 SMN1; SMN2 (0.59) EPHX1EPHX2MEN1KMT2AMAPT
SCHEMBL31349930 0.84 SMN1; SMN2 (0.79) EPHX2CA2NPC1MEN1KMT2A
SCHEMBL10814711 0.84 GAA (0.66) EPHX1EPHX2CYP3A4APEX1CA2
SCHEMBL3791892 0.84 ALDH1A1 (0.60) EPHX1MEN1KMT2AMAPTRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018091978-A1 A PROCESS FOR THE PREPARATION OF 2-NITRO-4,5- DICHLOROACETANILIDE AMOGH CHEMICALS PVT. LTD (IN) 2018-05-24 WO claimed
CN-105130872-B Preparation method of 3-trifluoromethyl substituted indole 江西师范大学 2018-01-30 CN claimed
US-11731933-B2 Device and method for the desalination of water by means of thermal deionisation and liquid-phase ion extraction liquid ADIONICS (FR) 2023-08-22 US disclosed
CN-112574054-B Efficient nitriding reagent and application thereof 北京大学 2022-10-14 CN disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
CN-112574054-A Efficient nitriding reagent and application thereof 北京大学 2021-03-30 CN disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed
CN-108069868-B Method for preparing organic amide compound from aryl diazo tetrafluoroborate and nitrile 湖南理工学院 2020-11-13 CN disclosed
WO-2018091978-A1 A PROCESS FOR THE PREPARATION OF 2-NITRO-4,5- DICHLOROACETANILIDE AMOGH CHEMICALS PVT. LTD (IN) 2018-05-24 WO disclosed
WO-2018091978-A1 A PROCESS FOR THE PREPARATION OF 2-NITRO-4,5- DICHLOROACETANILIDE AMOGH CHEMICALS PVT. LTD (IN) 2018-05-24 WO disclosed
EP-1147094-A1 NON-PEPTIDE GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2001-10-24 EP disclosed
US-6235730-B1 ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT JAPAN TOBACCO, INC. (JP) 2001-05-22 US disclosed
WO-2000042026-A1 NON-PEPTIDE GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2000-07-20 WO disclosed
EP-0970954-A1 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME JAPAN TOBACCO INC. (JP) 2000-01-12 EP disclosed
US-5646085-A AMINATION RHONE-POULENC CHIMIE (FR) 1997-07-08 US disclosed
US-4600797-A NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP BAYER AKTIENGESELLSCHAFT (DE) 1986-07-15 US disclosed
EP-0049711-B1 PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES BAYER AG (DE) 1984-02-29 EP disclosed
EP-0049711-A1 Process for the production of nitro-amino-benzenes BAYER AG (DE) 1982-04-21 EP disclosed
US-4160017-A EMETIC AGENTS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1979-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731933-B2 Device and method for the desalination of water by means of thermal deionisation and liquid-phase ion extraction liquid AQP3, AQP1, AQP4 EPHX1 2588/4885EPHX2 1663/4885CYP3A4 4048/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT EPHX1 405/4885EPHX2 818/4885CYP3A4 852/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT EPHX1 405/4885EPHX2 818/4885CYP3A4 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.